Display options
Cite
Michaud DS, Ruan M, Koestler DC, et al. Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI Cancer Spectr. 2020;4(5):pkaa041doi: 10.1093/jncics/pkaa041.
Michaud, D. S., Ruan, M., Koestler, D. C., Pei, D., Marsit, C. J., De Vivo, I., & Kelsey, K. T. (2020). Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI cancer spectrum, 4(5), pkaa041. https://doi.org/10.1093/jncics/pkaa041
Michaud, Dominique S, et al. "Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk." JNCI cancer spectrum vol. 4,5 (2020): pkaa041. doi: https://doi.org/10.1093/jncics/pkaa041
Michaud DS, Ruan M, Koestler DC, Pei D, Marsit CJ, De Vivo I, Kelsey KT. Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk. JNCI Cancer Spectr. 2020 May 19;4(5):pkaa041. doi: 10.1093/jncics/pkaa041. eCollection 2020 Oct. PMID: 33134824; PMCID: PMC7583152.
Copy Download .nbib Format: NLM
Share it on

JNCI Cancer Spectr. 2020 May 19;4(5):pkaa041. doi: 10.1093/jncics/pkaa041. eCollection 2020 Oct.

Epigenome-Wide Association Study Using Prediagnostic Bloods Identifies New Genomic Regions Associated With Pancreatic Cancer Risk.

JNCI cancer spectrum

Dominique S Michaud, Mengyuan Ruan, Devin C Koestler, Dong Pei, Carmen J Marsit, Immaculata De Vivo, Karl T Kelsey

Affiliations

  1. Department of Public Health & Community Medicine, Tufts University School of Medicine, Tufts University, Boston, MA, USA.
  2. Department of Epidemiology, Brown University, Providence, RI, USA.
  3. Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
  4. University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA.
  5. Department of Environmental Health and Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  6. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  7. Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.

PMID: 33134824 PMCID: PMC7583152 DOI: 10.1093/jncics/pkaa041

Abstract

BACKGROUND: Epigenome-wide association studies using peripheral blood have identified specific sites of DNA methylation associated with risk of various cancers and may hold promise to identify novel biomarkers of risk; however, few studies have been performed for pancreatic cancer and none using a prospective study design.

METHODS: Using a nested case-control study design, incident pancreatic cancer cases and matched controls were identified from participants who provided blood at baseline in 3 prospective cohort studies. DNA methylation levels were measured in DNA extracted from leukocytes using the Illumina MethylationEPIC array. Average follow-up period for this analysis was 13 years.

RESULTS: Several new genomic regions were identified as being differentially methylated in cases and controls; the 5 strongest associations were observed for CpGs located in genes

CONCLUSIONS: Changes in DNA methylation in peripheral blood may mark alterations in metabolic or immune pathways that play a role in pancreatic cancer. Identifying new biological pathways in carcinogenesis of pancreatic cancer using epigenome-wide association studies approach could provide new opportunities for improving treatment and prevention.

© The Author(s) 2020. Published by Oxford University Press.

References

  1. Cancer Prev Res (Phila). 2018 Nov;11(11):727-734 - PubMed
  2. Am J Hum Genet. 2017 Jul 6;101(1):5-22 - PubMed
  3. N Engl J Med. 2009 Apr 23;360(17):1699-701 - PubMed
  4. Bioinformatics. 2019 Jun 1;35(11):1958-1959 - PubMed
  5. Epigenetics Chromatin. 2015 Jan 27;8:6 - PubMed
  6. Mol Carcinog. 2012 Jan;51(1):109-18 - PubMed
  7. Genes Chromosomes Cancer. 2018 May;57(5):240-251 - PubMed
  8. Genome Biol. 2018 May 29;19(1):64 - PubMed
  9. PLoS One. 2012;7(5):e37509 - PubMed
  10. Ann Oncol. 2013 Nov;24(11):2903-10 - PubMed
  11. Clin Epigenetics. 2019 Apr 5;11(1):59 - PubMed
  12. BMC Bioinformatics. 2012 May 08;13:86 - PubMed
  13. J Biochem. 2000 Nov;128(5):847-53 - PubMed
  14. Database (Oxford). 2017 Jan 6;2017: - PubMed
  15. Epigenetics. 2018;13(10-11):1056-1071 - PubMed
  16. Oncol Lett. 2019 May;17(5):4474-4486 - PubMed
  17. PLoS One. 2012;7(10):e46705 - PubMed
  18. Cancer Epidemiol. 2014 Oct;38(5):576-82 - PubMed
  19. JAMA. 2019 Aug 6;322(5):438-444 - PubMed
  20. Cancer Res. 2014 Jun 1;74(11):2913-21 - PubMed
  21. Gastroenterology. 2010 Feb;138(2):541-9 - PubMed
  22. Cancer. 2010 Apr 1;116(7):1674-80 - PubMed
  23. Nat Commun. 2019 Jul 31;10(1):3417 - PubMed
  24. Science. 2017 Aug 18;357(6352): - PubMed
  25. Biomark Res. 2019 May 28;7:10 - PubMed
  26. J Natl Cancer Inst. 2015 Aug 22;107(11): - PubMed
  27. J Cell Physiol. 2018 Jun;233(6):4479-4489 - PubMed
  28. PLoS One. 2011 Mar 24;6(3):e18223 - PubMed
  29. Int J Cancer. 2007 Jan 15;120(2):368-72 - PubMed

Publication Types

Grant support